Tuesday, September 30, 2014
Merrimack (MACK) Reports Good News
Merrimack (MACK) provided updated clinical date on its compound MM-121. The drug initially showed a lack of statistical benefit in Phase 2 trails but the biomarker data has been analyzed and showed that the compound increased Progression Free Survival in patients with biomarker positive metatastic breast cancer by 74%. This is encouraging news for both the company and patients and I'd expect Merrimack to provide a strategic update on a pivotal trial in this patient subgroup in the future.